24 Apr Parkinson’s Disease: Extended Release Levodopa Tested to Reduce Motor Fluctuations
MedicalResearch.com Interview with:
Alberto J. Espay, MD, MSc, FAAN
Professor of Neurology
Director and Endowed Chair
Gardner Family Center for Parkinson’s disease and Movement Disorders
University of Cincinnati Academic Health Center
MedicalResearch.com: What is the background for this study?
Response: This study was meant to address the gap that current oral levodopa formulations do not suffice to lessen motor fluctuations in people with Parkinson’s disease. IPX203 is a unique extended-release formulation of levodopa.
MedicalResearch.com: What are the main findings?
Response: IPX203 dosed at three daily doses was safe and extended the “on time” compared to five daily doses of standard levodopa.
MedicalResearch.com: What should readers take away from your report?
Response: We have shown that such response is sustained for at least the 9 months of open-label extension data we are presenting.
MedicalResearch.com: What recommendations do you have for future research as a results of this study?
Response: Future research may test the value of using IPX203 earlier in the disease, even prior to the development of motor fluctuations.
Disclosures: I was a primary investigator for the IPX203 and have received compensation as scientific advisor from Amneal, the owner of IPX203.
Citation: AAN 2023 abstract
Long-term Safety and Efficacy of IPX203 in Parkinson’s Disease Patients with Motor Fluctuations: A 9-Month Open-label Extension Trial
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.